ESCMID 免疫功能受损宿主感染研究组(ESGICH)关于靶向治疗和生物制剂治疗安全性的共识文件:感染病学视角(引言)
该共识文件由 ESCMID 免疫功能受损宿主感染研究组(ESGICH)发起,从感染病学视角分析靶向治疗和生物制剂的安全性。文件按药物靶点分类,每类涵盖作用机制、适应症、对宿主感染易感性的影响、临床证据及推荐的预防与风险最小化策略。
要点
- 文件按药物靶向作用位点分类,包括促炎细胞因子、白细胞介素与免疫球蛋白等。
- 每种药物概述作用机制、获批适应症、超说明书使用及对感染易感性的预期影响。
- 汇总关键临床试验、上市后研究、病例系列和病例报告等临床证据。
核心结论
- 该共识文件既全面概述了获批靶向治疗相关感染风险的分子原理和临床经验,也尝试提出一系列推荐以指导不同学科医生。
研究设计与样本
- ESCMID 免疫功能受损宿主感染研究组(ESGICH)发起的共识文件,基于计算机 Medline 检索(MeSH 主题词涉及每种药物或治疗家族)。
主要发现
- 文件按药物靶向作用位点分为促炎细胞因子、白细胞介素/免疫球蛋白及其他可溶性免疫介质、细胞表面受体及相关信号通路、细胞内信号通路、淋巴瘤和白血病细胞表面抗原及其他靶向治疗等部分。
- 每种药物按统一框架总结作用机制、获批适应症和常见超说明书使用、对宿主感染易感性的预期影响、现有临床证据及建议的预防和风险最小化策略。
- 文件还讨论了评估特定药物所致特定风险的方法学和实践困难。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The field of new biological agents is increasing exponentially over the past years, thus making prevention and management of associated infectious complications a challenge for nonspecialized clinicians. AIMS: The present consensus document is an initiative of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Infections in Compromised Hosts (ESGICH) aimed at analysing, from an infectious diseases perspective, the safety of targeted and biological therapies. SOURCES: Computer-based Medline searches with MeSH terms pertaining to each agent or therapeutic family. CONTENT: The document is structured in sections according to the targeted site of action of each drug class: proinflammatory cytokines; interleukins, immunoglobulins and other soluble immune mediators; cell surface receptors and associated signaling pathways; intracellular signaling pathways; lymphoma and leukaemia cells surface antigens; and other targeted therapies. A common outline is followed for each agent: summary of mechanism of action, approved indications and common off-label uses; expected impact on the host's susceptibility to infection; available clinical evidence (i.e. pivotal clinical trials, postmarketing studies, case series and case reports); and suggested prevention and risk minimization strategies. The methodologic and practical difficulties of assessing the specific risk posed by a given agent are also discussed. IMPLICATIONS: This ESGICH consensus document constitutes not only a comprehensive overview of the molecular rationale and clinical experience on the risk of infection associated with approved targeted therapies but also an attempt to propose a series of recommendations with the purpose of guiding physicians from different disciplines into this emerging framework.
引用
- Fernández-Ruiz M, Meije Y, Manuel O, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Introduction). Clin Microbiol Infect. 2018. PMID: 29427801. doi:10.1016/j.cmi.2018.01.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。